-
A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity Eur. Heart J. (IF 29.983) Pub Date : 2022-06-27 Dongchao Lu, Shambhabi Chatterjee, Ke Xiao, Isabelle Riedel, Cheng Kai Huang, Alessia Costa, Sarah Cushman, Dimyana Neufeldt, Laura Rode, Arne Schmidt, Malte Juchem, Julia Leonardy, Gwen Büchler, Jonas Blume, Olivia Luise Gern, Ulrich Kalinke, Wilson Lek Wen Tan, Roger Foo, Aryan Vink, Linda W van Laake, Peter van der Meer, Christian Bär, Thomas Thum
Aims Cardiotoxicity leading to heart failure (HF) is a growing problem in many cancer survivors. As specific treatment strategies are not available, RNA discovery pipelines were employed and a new and powerful circular RNA (circRNA)-based therapy was developed for the treatment of doxorubicin-induced HF. Methods and results The circRNA sequencing was applied and the highly species-conserved circRNA
-
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial Eur. Heart J. (IF 29.983) Pub Date : 2022-06-25 Masatsugu Hori, Jun Zhu, Yan Liang, Deepak L Bhatt, Jackie Bosch, Stuart J Connolly, Keith A A Fox, Aldo Maggioni, Salim Yusuf, John W Eikelboom
Aims It is unknown whether Asian and non-Asian patients with atherosclerotic vascular disease derive similar benefits from long-term antithrombotic therapy. Methods and results In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2.5 mg b.i.d
-
Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC Registry Eur. Heart J. (IF 29.983) Pub Date : 2022-06-21 Karishma P Ramlakhan, Isabelle Malhamé, Ariane Marelli, Tobias Rutz, Sorel Goland, Arie Franx, Karen Sliwa, Uri Elkayam, Mark R Johnson, Roger Hall, Jérôme Cornette, Jolien W Roos-Hesselink
Aims Hypertensive disorders of pregnancy (HDP) occur in 10% of pregnancies in the general population, pre-eclampsia specifically in 3–5%. Hypertensive disorders of pregnancy may have a high prevalence in, and be poorly tolerated by, women with heart disease. Methods and results The prevalence and outcomes of HDP (chronic hypertension, gestational hypertension or pre-eclampsia) were assessed in the
-
Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice? Eur. Heart J. (IF 29.983) Pub Date : 2022-06-21 Domenico Corrado, Mark S Link, Peter J Schwartz
Many previously unexplained life-threatening ventricular arrhythmias and sudden cardiac deaths (SCDs) in young individuals are now recognized to be genetic in nature and are ascribed to a growing number of distinct inherited arrhythmogenic diseases. These include hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular
-
Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy Eur. Heart J. (IF 29.983) Pub Date : 2022-06-21 Isaac Perea-Gil, Timon Seeger, Arne A N Bruyneel, Vittavat Termglinchan, Emma Monte, Esther W Lim, Nirmal Vadgama, Takaaki Furihata, Alexandra A Gavidia, Jennifer Arthur Ataam, Nike Bharucha, Noel Martinez-Amador, Mohamed Ameen, Pooja Nair, Ricardo Serrano, Balpreet Kaur, Dries A M Feyen, Sebastian Diecke, Michael P Snyder, Christian M Metallo, Mark Mercola, Ioannis Karakikes
Aims Genetic dilated cardiomyopathy (DCM) is a leading cause of heart failure. Despite significant progress in understanding the genetic aetiologies of DCM, the molecular mechanisms underlying the pathogenesis of familial DCM remain unknown, translating to a lack of disease-specific therapies. The discovery of novel targets for the treatment of DCM was sought using phenotypic sceening assays in induced
-
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease Eur. Heart J. (IF 29.983) Pub Date : 2022-06-17 Arjun K Pandey, Deepak L Bhatt, Francesco Cosentino, Nikolaus Marx, Ori Rotstein, Bertram Pitt, Ambirash Pandey, Javed Butler, Subodh Verma
Despite existing treatments, patients with heart failure and chronic kidney disease (CKD) remain at high risk for adverse outcomes and progression to end-stage disease. Steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone reduce mortality but remain under-prescribed due to the perceived risk of hyperkalaemia and hormonal side effects. The discovery of non-steroidal
-
Aortic arch aneurysm isolated by percutaneous total endovascular arch replacement. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-16 Dan Rong,Hongpeng Zhang,Wei Guo
-
Challenges of diversity and inclusion and the need for change. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-16 Estefania Oliveros,Stephen McHugh,Daniel Brito,Clyde Yancy
-
Additional value of 18fluorodeoxyglucose positron emission tomography/computed tomography combined with intracardiac echocardiography to detect lead vegetations. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-16 Floris J Heinen,Wilco Tanis
-
Emergency surgery for neonatal double aortic arch complicated with severe tracheal stenosis under prenatal ultrasound guidance. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-16 Yuhang Liu,Ning Wang,Yan Liu,Ping Wen
-
Functional stress imaging to predict abnormal coronary fractional flow reserve: the PACIFIC 2 study Eur. Heart J. (IF 29.983) Pub Date : 2022-06-16 Roel S Driessen, Pepijn A van Diemen, Pieter G Raijmakers, Juhani Knuuti, Teemu Maaniitty, S Richard Underwood, Eike Nagel, Lourens F H J Robbers, Ahmet Demirkiran, Martin B von Bartheld, Peter M van de Ven, Leonard Hofstra, G Aernout Somsen, Igor I Tulevski, Ronald Boellaard, Albert C van Rossum, Ibrahim Danad, Paul Knaapen
Aims The diagnostic performance of non-invasive imaging in patients with prior coronary artery disease (CAD) has not been tested in prospective head-to-head comparative studies. The aim of this study was to compare the diagnostic performance of qualitative single-photon emission computed tomography (SPECT), quantitative positron emission tomography (PET), and qualitative magnetic resonance imaging
-
Single versus multiple arterial grafting in diabetic patients at 10 years: the Arterial Revascularization Trial. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-14 David P Taggart,Katia Audisio,Stephen Gerry,N Bryce Robinson,Mohamed Rahouma,Giovanni Jr Soletti,Gianmarco Cancelli,Umberto Benedetto,Belinda Lees,Alastair Gray,Maria Stefil,Marcus Flather,Mario Gaudino,
AIMS To evaluate the impact of multiple arterial grafting (MAG) vs. single arterial grafting (SAG) in a post hoc analysis of 10-year outcomes in patients with diabetes mellitus (DM) from the Arterial Revascularization Trial (ART). METHODS AND RESULTS The primary endpoint was all-cause mortality and the secondary endpoint was a composite of major adverse cardiac events (MACE) at 10-year follow-up. Patients
-
The complex link among heart failure, atrial fibrillation, and lung diseases, and an update on cardiac transplantation. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-14 Filippo Crea
-
Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry Eur. Heart J. (IF 29.983) Pub Date : 2022-06-13 William K.F. Kong, Antonio Salsano, Daniele Roberto Giacobbe, Bogdan A. Popescu, Cécile Laroche, Xavier Duval, Robert Schueler, Antonella Moreo, Paolo Colonna, Cornelia Piper, Francisco Calvo-Iglesias, Luigi P. Badano, Ilija Srdanovic, David Boutoille, Olivier Huttin, Elisabeth Stöhr, Ana Teresa Timóteo, Jolanta-Justina Vaskelyte, Anita Sadeghpour, Pilar Tornos, Leila Abid, Kian Keong Poh, Gilbert
Aim Fatality of infective endocarditis (IE) is high worldwide, and its diagnosis remains a challenge. The objective of the present study was to compare the clinical characteristics and outcomes of patients with culture-positive (CPIE) vs. culture-negative IE (CNIE). Methods and results This was an ancillary analysis of the ESC-EORP EURO-ENDO registry. Overall, 3113 patients who were diagnosed with
-
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled Eur. Heart J. (IF 29.983) Pub Date : 2022-06-10 João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filipattos, Ivana Ritter, Elke Schüler, Bettina J Kraus, Stuart J. Pocock, Stefan D. Anker, Milton Packer
Aims Hyperkalaemia frequently leads to interruption and discontinuation of neurohormonal antagonists, which may worsen heart failure prognosis. Some studies suggested that sodium-glucose cotransporter 2 inhibitors reduce hyperkalaemia, an effect that may have important clinical implications. This analysis evaluates the effect of empagliflozin on the occurrence of hyper- and hypokalaemia in HF. Methods
-
The cardiovascular legacy of the COVID-19 pandemic. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-10 Ankeet S Bhatt,Muthiah Vaduganathan
-
Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-10 Subodh Verma,Nitish K Dhingra,Arjun K Pandey,Francesco Cosentino
-
A double negative: culture-negative infective endocarditis. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-09 Emil L Fosbøl
-
Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome? Eur. Heart J. (IF 29.983) Pub Date : 2022-06-09 Wout W A van den Broek,Jurriën M Ten Berg
-
Significant ethical considerations with cardiac arrest resuscitation by dispatched volunteer rescuers. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-09 Aditya C Shekhar
-
Ethical and organizational considerations: the next step in the implementation of volunteer responder programmes. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-09 Linn Andelius,Fredrik Folke,Carolina Malta Hansen
-
Right ventricular diverticulum: an uncommon cause of chest pain. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-08 Xiaoling Zhang,Zhiyue Liu,Yeting Bian,He Huang
-
A new score for life-threatening ventricular arrhythmias and sudden cardiac death in adults with transposition of the great arteries and a systemic right ventricle Eur. Heart J. (IF 29.983) Pub Date : 2022-06-08 Magalie Ladouceur, Alexander Van De Bruaene, Robert Kauling, Werner Budts, Jolien Roos-Hesselink, Sandra Villagrá Albert, Inmaculada Sanchez Perez, Berardo Sarubbi, Flavia Fusco, Pastora Gallego, Maria-Jose Rodriguez-Puras, Judith Bouchardy, Coralie Blanche, Tobias Rutz, Katja Prokselj, Fabien Labombarda, Laurence Iserin, Tom Wong, Michael A. Gatzoulis
Aims To investigate the incidence of major adverse ventricular arrhythmias and related events (MAREs) and to develop a stratification tool predicting MAREs in adults with a systemic right ventricle (sRV). Methods and results In a multicentre approach, all adults (≥16 years old) with a sRV undergoing follow-up between 2000 and 2018 were identified. The incidence of MAREs, defined as sudden cardiac death
-
Isolated posterior mitral leaflet elongation-related dynamic left ventricular outflow obstruction. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-08 Chinmay Parale,A Shaheer Ahmed,Akinchan Bhardwaj
-
Sudden cardiac death in adults with transposition of the great arteries and systemic right ventricles: preventing (night)MAREs. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-08 Paul Khairy
-
Subtotal obstruction of the left coronary ostium by chronic neo-intimal ingrowth. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-08 Aljona Friedrich,Miralem Pasic,Volkmar Falk
-
Bernard Gersh and Paul Friedman on the future of artificial intelligence in cardiology. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-08 Emma Luisa Hempstead
-
A rose by any other name would smell as sweet † ; does nomenclature matter? Eur. Heart J. (IF 29.983) Pub Date : 2022-06-06 Peter Lanzer,Yu Sato,Renu Virmani
-
New avenues in the prevention of sudden cardiac death. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-06 Filippo Crea
-
Cardiac xenotransplantation: a new path for the treatment of advanced heart failure? Eur. Heart J. (IF 29.983) Pub Date : 2022-06-04 Eugene Braunwald
-
The challenge of cardiovascular prevention in the elderly: importance of randomized clinical trials. Eur. Heart J. (IF 29.983) Pub Date : 2022-06-01 Filippo Crea
-
Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial Eur. Heart J. (IF 29.983) Pub Date : 2022-05-31 Sashiananthan Ganesananthan, Christopher A. Rajkumar, Michael Foley, David Thompson, Alexandra N. Nowbar, Henry Seligman, Ricardo Petraco, Sayan Sen, Sukhjinder Nijjer, Simon A. Thom, Roland Wensel, John Davies, Darrel Francis, Matthew Shun-Shin, James Howard, Rasha Al-Lamee
Aims Oxygen-pulse morphology and gas exchange analysis measured during cardiopulmonary exercise testing (CPET) has been associated with myocardial ischaemia. The aim of this analysis was to examine the relationship between CPET parameters, myocardial ischaemia and anginal symptoms in patients with chronic coronary syndrome and to determine the ability of these parameters to predict the placebo-controlled
-
Critical appraisal of artificial intelligence-based prediction models for cardiovascular disease. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-26 Maarten van Smeden,Georg Heinze,Ben Van Calster,Folkert W Asselbergs,Panos E Vardas,Nico Bruining,Peter de Jaegere,Jason H Moore,Spiros Denaxas,Anne-Laure Boulesteix,Karel G M Moons
The medical field has seen a rapid increase in the development of artificial intelligence (AI)-based prediction models. With the introduction of such AI-based prediction model tools and software in cardiovascular patient care, the cardiovascular researcher and healthcare professional are challenged to understand the opportunities as well as the limitations of the AI-based predictions. In this article
-
Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-26 Claudio Rapezzi,Matteo Serenelli,Alberto Aimo
-
Three-dimensional printing, holograms, computational modelling, and artificial intelligence for adult congenital heart disease care: an exciting future. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-24 Massimo Chessa,Alexander Van De Bruaene,Kanwal Farooqi,Israel Valverde,Christian Jung,Emiliano Votta,Francesco Sturla,Gerhard Paul Diller,Margarita Brida,Zhonghua Sun,Stephen H Little,Michael A Gatzoulis
Congenital heart disease (CHD) is often comprised of complex three-dimensional (3D) anatomy that must be well understood to assess the pathophysiological consequences and guide therapy. Thus, detailed cardiac imaging for early detection and planning of interventional and/or surgical treatment is paramount. Advanced technologies have revolutionized diagnostic and therapeutic practice in CHD, thus playing
-
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-22 Marco Metra,Matteo Pagnesi,Brian L Claggett,Rafael Díaz,G Michael Felker,John J V McMurray,Scott D Solomon,Diana Bonderman,James C Fang,Cândida Fonseca,Eva Goncalvesova,Jonathan G Howlett,Jing Li,Eileen O'Meara,Zi Michael Miao,Siddique A Abbasi,Stephen B Heitner,Stuart Kupfer,Fady I Malik,John R Teerlink
AIM Patients with heart failure with reduced ejection fraction and low systolic blood pressure (SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical treatment. Omecamtiv mecarbil may be particularly helpful in such patients. This study examined its efficacy and tolerability in patients with SBP ≤100 mmHg enrolled in the Global Approach to Lowering Adverse Cardiac outcomes
-
A laboratory viewpoint of the consensus paper from the European Society of Cardiology regarding the utilization of the American College of Medical Genetics and Genomics pathogenic criteria for cardiomyopathy. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-22 Yi Ma,Hang Yang,Zongzhe Li
-
Interpretation of genetic variants depends on a clinically guided integration of phenotype and molecular data. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-22 Eloisa Arbustini,Mario Urtis,Perry Elliott
-
A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-22 Søren P Johnsen,Marco Proietti,Aldo P Maggioni,Gregory Y H Lip
-
The promise of the metaverse in cardiovascular health. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-22 Bertalan Mesko
-
Doubly committed ventricular septal defect closure using an eccentric occluder via minimal incision in the anterior median sternum through the left parasternal third intercostal space. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-22 Xuning Lu,Ping Wen,Quansheng Xing
-
Challenges in heart failure: from actionability of genetic variants in cardiopmyopathies to new therapeutic targets. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-21 Filippo Crea
-
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-18 Jean-Philippe Collet,Eric Van Belle,Holger Thiele,Sergio Berti,Thibault Lhermusier,Thibault Manigold,Franz-Josef Neumann,Martine Gilard,David Attias,Farzin Beygui,Angel Cequier,Fernando Alfonso,Pierre Aubry,Flore Baronnet,Stéphane Ederhy,Mohamad El Kasty,Mathieu Kerneis,Olivier Barthelemy,Thierry Lefèvre,Pascal Leprince,Alban Redheuil,Patrick Henry,Jean-Jacques Portal,Eric Vicaut,Gilles Montalescot
AIMS The respective roles of oral anticoagulation or antiplatelet therapy following transcatheter aortic valve implantation (TAVI) remain debated. ATLANTIS is an international, randomized, open-label, superiority trial comparing apixaban to the standard of care. METHODS AND RESULTS After successful TAVI, 1500 patients were randomized (1:1) to receive apixaban 5 mg (2.5 mg if impaired renal function
-
Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-18 Felicita Andreotti,Massimo Massetti,Jurrien Ten Berg
-
Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention In Patients at High Bleeding Risk: a MASTER DAPT trial sub-analysis. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-17 Marco Valgimigli,Pieter C Smits,Enrico Frigoli,Dario Bongiovanni,Jan Tijssen,Thomas Hovasse,Al Mafragi,W T Ruifrok,Dimitar Karageorgiev,Adel Aminian,Stefano Garducci,Bela Merkely,Helen Routledge,Kenji Ando,Josè Francisco Diaz Fernandez,Thomas Cuisset,Fazila Tun Nesa Malik,Majdi Halabi,Loic Belle,Jehangir Din,Farzin Beygui,Atul Abhyankar,Krzysztof Reczuch,Giovanni Pedrazzini,Dik Heg,Pascal Vranckx,
AIMS To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS). METHODS AND RESULTS In the MASTER DAPT trial, 3383 patients underwent noncomplex (abbreviated DAPT, n = 1707; standard DAPT, n = 1676)
-
Cardiovascular magnetic resonance for the assessment of left ventricular filling pressure in heart failure. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-16 Anna Baritussio,Vivek Muthurangu
-
Puncture of the anterior wall of the pericardium by a fish bone from an oesophageal perforation. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-16 Jian Zhu,Shui-Bo Zhu,Er-Ping Xi
-
The fractionated QRS complex for cardiovascular risk assessment. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-16 Richard N W Hauer
-
Global impact of deep vein thrombosis awareness month: challenges and future recommendations. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-16 Kashish Malhotra,Ashvind Bawa,Kashish Goyal,Gurpreet Singh Wander
-
New therapeutic targets to reduce inflammation-associated cardiovascular risk: the CCL2-CCR2 axis, LOX-1, and IRF5. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-14 Filippo Crea
-
Timing of cardiac surgery during pregnancy: a patient-level meta-analysis. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-13 Gijs J van Steenbergen,Queeny H Y Tsang,Olivier W H van der Heijden,Priya Vart,Laura Rodwell,Jolien W Roos-Hesselink,Roland R J van Kimmenade,Wilson W L Li,Ad F T M Verhagen
AIMS To investigate the association between the timing of cardiac surgery during pregnancy and both maternal and foetal outcomes. METHODS AND RESULTS Studies published up to 6 February 2021 on maternal and/or foetal mortality after cardiac surgery during pregnancy that included individual patient data were identified. Maternal and foetal mortality was analysed per trimester for the total population
-
T cells: a 'hidden corner' to be explored for treating heart failure. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-13 Yike Zhu,Matthew Ackers-Johnson,Roger Foo
-
Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-13 Gregory Y H Lip,Deirdre A Lane,Radosław Lenarczyk,Giuseppe Boriani,Wolfram Doehner,Laura A Benjamin,Marc Fisher,Deborah Lowe,Ralph L Sacco,Renate Schnabel,Caroline Watkins,George Ntaios,Tatjana Potpara
The management of patients with stroke is often multidisciplinary, involving various specialties and healthcare professionals. Given the common shared risk factors for stroke and cardiovascular disease, input may also be required from the cardiovascular teams, as well as patient caregivers and next-of-kin. Ultimately, the patient is central to all this, requiring a coordinated and uniform approach
-
Treatment of mild hypertension improves pregnancy outcomes. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-13 Leonarda Galiuto,Massimo Volpe
-
A novel inhibitor of Factor XIa as potential haemostasis-sparing anticoagulant for patients with atrial fibrillation. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-13 Giovanna Liuzzo,Carlo Patrono
-
Acute necrotizing eosinophilic myocarditis after COVID-19 vaccination. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-13 Kisho Ohtani,Soichiro Takahama,Seiya Kato,Taiki Higo
-
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis Eur. Heart J. (IF 29.983) Pub Date : 2022-05-09 Steven Law, Melanie Bezard, Aviva Petrie, Liza Chacko, Oliver C. Cohen, Sriram Ravichandran, Olabisi Ogunbiyi, Mounira Kharoubi, Sashiananthan Ganeshananthan, Sharmananthan Ganeshananthan, Janet A. Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez-Naharro, Helen J. Lachmann, Carol J. Whelan, David F. Hutt, Philip N. Hawkins, Thibaud Damy, Marianna Fontana, Julian D. Gillmore
Aims Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed at an early stage of the disease natural history, defined as National Amyloidosis Centre (NAC) ATTR Stage I. The natural history of early-stage ATTR-CM remains poorly characterized. Methods and results A retrospective multi-centre observational study of 879 patients with ATTR-CM, either wild-type TTR genotype or carrying
-
The risk of 'hidden' sodium and of low vitamin D levels. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-07 Filippo Crea
-
The Atrial Fibrillation Heart Team-guiding therapy in left atrial appendage occlusion with increasingly complex patients and little evidence. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-07 Shinwan Kany,Andreas Metzner,Edith Lubos,Paulus Kirchhof
-
Autopsy in the era of advanced cardiovascular imaging. Eur. Heart J. (IF 29.983) Pub Date : 2022-05-06 Cristina Basso,James R Stone
Historically, autopsy contributed to our current knowledge of cardiovascular anatomy, physiology, and pathology. Major advances in the understanding of cardiovascular diseases, including atherosclerosis and coronary artery disease, congenital heart diseases, and cardiomyopathies, were possible through autopsy investigations and clinicopathological correlations. In this review, the importance of performing